2025-03-01
2024-05-19
| Summary | |
|---|---|
| Cancer Type | Prostate Cancer |
| Grade | NA |
| Stage | G4+5, T4, N1 |
| Ethnicity | Western |
| Gender | M |
| Age | 78 |
| Pathology Diagnosis | Castrate-resistant prostate cancer (CRPC). |
| Biopsy Site | primary |
| Treatment History | HT |
| Pathology QC | Poorly differentiated carcinoma with massive necrosis(PR6511-H455/4 30/8), poorly differentiated carcinoma with part of papillary structure (PR6511-H455/4+C 8/11), poorly differentiated prostate adenocarcinoma; P504(2~3+), 34bE12(nearly 1~2%: 1+), CK8(3+), PSA(1~2+), Nkx3.1(3+), AR(3+), p63(1+). |
| Special Features | CRPC, model expansion is needed prio to study. |
| Mouse Strain | Rag2-/-?C-/-, NSG |
| TMA | NA |
| Viral Status in PDX | NA |
| Available In | CB_UK |
| RNA Seq | P4 |
| Exome Seq | P3 |
Already Registered? Login
To view this data, close this window and Log In or Register for Access.
© 2025 Crown Bioscience. All Rights Reserved.
Privacy Policy | Imprint | Terms of Service | Privacy Preferences


© 2025 Crown Bioscience. All Rights Reserved. Privacy Policy